UTHR · NASDAQ
United Therapeutics (UTHR) Stock Price & Fundamentals
United Therapeutics (UTHR) closed at $792.63 on Oct 9, 2026, up 0.75% from the previous close of $786.71.
Share price, past year
1Y +21.20%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $792.63 |
| Sep 30, 2026 | $759.15 |
| Aug 31, 2026 | $731.37 |
| Jul 31, 2026 | $697.24 |
| Jun 30, 2026 | $708.40 |
| May 29, 2026 | $699.84 |
| Apr 30, 2026 | $697.33 |
| Mar 31, 2026 | $699.79 |
| Feb 27, 2026 | $639.96 |
| Jan 30, 2026 | $621.67 |
| Dec 31, 2025 | $643.31 |
| Nov 28, 2025 | $627.34 |
| Oct 31, 2025 | $636.81 |
Key statistics
- Market cap
- $33.83B
- P/E (TTM)
- 28.4
- EPS (TTM)
- $27.91
- Revenue (TTM)
- $3.15B
- Net income (TTM)
- $1.31B
- Shares outstanding
- 42.7M
- Dividend yield
- —
- 52-week range
- $613.18 – $792.63
United Therapeutics's market cap is $33.83B, based on a share price of $792.63 and 42.7M shares outstanding as of Jun 30, 2026.
Financials
United Therapeutics reported revenue of $3.18B for fiscal 2025, up 10.61% from fiscal 2024.
United Therapeutics earned net income of $1.33B in fiscal 2025, a net margin of 41.9%.
Fiscal 2025 revenue was the highest in the 10 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $3.18B | +10.6% | $1.33B | 41.9% | $27.86 | $1.04B |
| FY2024ended Dec 31, 2024 | $2.88B | +23.6% | $1.20B | 41.5% | $24.64 | $1.08B |
| FY2023ended Dec 31, 2023 | $2.33B | +20.2% | $984.80M | 42.3% | $19.81 | $747.60M |
| FY2022ended Dec 31, 2022 | $1.94B | +14.9% | $727.30M | 37.6% | $15.00 | $663.70M |
| FY2021ended Dec 31, 2021 | $1.69B | +13.6% | $475.80M | 28.2% | $10.06 | $477.40M |
| FY2020ended Dec 31, 2020 | $1.48B | +2.4% | — | — | $11.54 | $696.40M |
| FY2019ended Dec 31, 2019 | $1.45B | −11.0% | — | — | −$2.39 | −$290.30M |
| FY2018ended Dec 31, 2018 | $1.63B | −5.7% | — | — | $13.39 | $594.00M |
| FY2017ended Dec 31, 2017 | $1.73B | +7.9% | — | — | $9.31 | $387.90M |
| FY2016ended Dec 31, 2016 | $1.60B | — | — | — | $15.25 | $605.60M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $783.30M | $333.00M | $7.27 |
| Q1 FY2026ended Mar 31, 2026 | $781.50M | $274.90M | $5.82 |
| Q4 FY2025ended Dec 31, 2025 | $790.20M | $364.30M | $7.66 |
| Q3 FY2025ended Sep 30, 2025 | $799.50M | $338.70M | $7.16 |
| Q2 FY2025ended Jun 30, 2025 | $798.60M | $309.50M | $6.41 |
| Q1 FY2025ended Mar 31, 2025 | $794.40M | $322.20M | $6.63 |
| Q4 FY2024ended Dec 31, 2024 | $735.90M | $301.30M | $6.23 |
| Q3 FY2024ended Sep 30, 2024 | $748.90M | $309.10M | $6.39 |
Company profile
- Name
- UNITED THERAPEUTICS Corp
- Ticker
- UTHR
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 1000 Spring St, Silver Spring, MD 20910
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001082554
Recent SEC filings
- Sep 8, 2026
- Aug 5, 2026
- Aug 5, 2026
- Jul 23, 2026
- Jun 29, 2026
- May 6, 2026
- May 6, 2026
- Mar 30, 2026
Frequently asked questions
What is United Therapeutics's stock price?
United Therapeutics (UTHR) closed at $792.63 on Oct 9, 2026, up 0.75% from the previous close of $786.71.
What is United Therapeutics's market cap?
United Therapeutics's market cap is $33.83B, based on a share price of $792.63 and 42.7M shares outstanding as of Jun 30, 2026.
How much revenue does United Therapeutics make?
United Therapeutics reported revenue of $3.18B for fiscal 2025, up 10.61% from fiscal 2024.
What is UTHR's P/E ratio?
United Therapeutics's price-to-earnings ratio is 28.4, based on trailing twelve-month diluted EPS of $27.91.
Does United Therapeutics pay a dividend?
United Therapeutics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from UNITED THERAPEUTICS Corp's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures